Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07754916

Comparison of Liposomal Bupivacaine Paravertebral Nerve Block Versus Intercostal Nerve Block on Postoperative Glycemic Variability in Patients Undergoing Minimally Invasive Pulmonary Resection: A Randomized Controlled Non-Inferiority Trial

In this randomized controlled non-inferiority trial, we will test whether liposomal bupivacaine intercostal nerve block is non-inferior to paravertebral nerve block for the coefficient of variation (CV) of glucose during the 0- to 48-hour postoperative period, using a non-inferiority margin of Δ = 0.025 for the absolute CV difference. We will also compare the two blocks regarding their effects on postoperative glucose, autonomic function, stress, insulin resistance, acute pain, recovery quality, procedure duration, complications, and hemodynamic stability.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 18-70 years, with American Society of Anesthesiologists (ASA) physical status I-III, scheduled for uniportal or multiportal video-assisted thoracoscopic (VATS) minimally invasive pulmonary resection under general anesthesia.
  • Planned to receive liposomal bupivacaine regional block analgesia under direct thoracoscopic visualization.
  • Body mass index (BMI) 18-30 kg/m².
  • Willing and able to cooperate with the study procedures and provide written informed consent.

Exclusion criteria

  • Regularly taking beta-blockers (for ≥2 weeks) or long-term use of high-dose glucocorticoids (prednisone ≥20 mg/day for >2 weeks).
  • Known history of diabetes mellitus, or regular use of glucose-lowering agents (oral agents or insulin) before surgery.
  • Planned postoperative admission to the intensive care unit (ICU).
  • Concurrent severe cardiac (New York Heart Association class III or higher), hepatic (e.g., cirrhosis), or renal insufficiency (glomerular filtration rate <30 mL/min/1.73 m²), or neuropsychiatric disorders.
  • Contraindications to regional block or to any study medication, including but not limited to infection or tumor invasion at the puncture site, coagulation disorders, or allergy to any drug used in the study.
  • Alcohol dependence: meeting the DSM-5 criteria for severe alcohol use disorder (AUD), or clinically judged as alcohol dependence (regardless of liver function status).
  • Pregnancy or lactation (for men and women of childbearing potential, effective contraception is required until 3 months after surgery, and donation of sperm or eggs is prohibited).
  • Participation in another interventional drug trial.
  • Regular use of analgesics for acute or chronic pain within 2 weeks before surgery.
  • Concurrent severe infection.
  • Prior ipsilateral intrathoracic surgery or severe pleural adhesions (estimated to preclude successful thoracoscopic visualization and completion of the block).
  • Psychiatric or cognitive disorders that would impair the ability to cooperate with postoperative follow-up.
  • Any other condition that, in the investigator's judgment, would make the patient unsuitable for participation in the trial (for medical or safety reasons).

Treatment and study plan

Paravertebral Nerve Block

Procedure

Following induction of general anesthesia, a T3-T8 paravertebral nerve block will be performed by the surgeon under thoracoscopic guidance. Liposomal bupivacaine (6.65 mg/mL) will be diluted with normal saline (20 mL + 20 mL = 40 mL total). Under direct vision, 4.0 mL of the diluted solution will be injected evenly at each level, lateral to the sympathetic chain, for a total liposomal bupivacaine dose of 159.6 mg (24 mL). Injections will be slow and fractionated, with aspiration for blood or cerebrospinal fluid prior to each injection, and care will be taken to prevent overdose and systemic toxicity.

Intercostal Nerve Block

Procedure

Following induction of general anesthesia, the surgeon will perform thoracoscopic intercostal nerve blocks using liposomal bupivacaine (prepared as 20 mL of 6.65 mg/mL solution diluted with 20 mL normal saline to 40 mL total) to cover the surgical incision and pleural irritation areas, typically at the 3rd-8th intercostal spaces. Under direct vision, 4.0 mL of the diluted solution will be injected at each space at a site 3-5 cm lateral to the spine, for a total liposomal bupivacaine dose of 159.6 mg (24 mL). Injections will be slow and fractionated, with aspiration for blood or CSF before each injection, and care will be taken to prevent overdose and systemic toxicity.

Primary outcomes

  1. Coefficient of Variation of Blood Glucose

    Time frame: 48 hours post-surgery

Secondary outcomes

  1. Glycated Serum Protein (GSP)

    Time frame: Preoperatively and on the first postoperative day

  2. Heart Rate Variability

    Time frame: Preoperatively and on the first postoperative day, the second postoperative day, and the third postoperative day

  3. Fasting Serum Insulin

    Time frame: Preoperatively and on the first postoperative day

  4. Numerical Rating Scale (NRS) Pain Score

    Time frame: Preoperatively and on the first postoperative day, the second postoperative day, and the third postoperative day

    Numerical Rating Scale (NRS) Pain Score Scale range: 0 (no pain) to 10 (worst imaginable pain). Higher scores indicate more severe pain.

  5. Fasting C peptide

    Time frame: Preoperatively and on the first postoperative day

  6. Cortisol

    Time frame: Preoperatively and on the first postoperative day

Study contacts

Contact information is provided by the study sponsor or research team.

Hongying Zhu

CONTACT

[email protected]

+86-15970330540

Yingqi Weng, MD

CONTACT

[email protected]

+86-15074834690

Sponsors and collaborators

Lead sponsor

Xiangya Hospital of Central South University

Other

Registry information

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Aug 10, 2026
Registry last updated
Aug 10, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.